News CHICAGO (April 20, 2023) – ADM (NYSE: ADM), a global leader in human and animal nutrition, announced today it has...
Announcing the appointment of two highly respected individuals as senior advisors to our management team. Prof. James Rothman, Nobel Laureate...
Zürich to accelerate the development of Gnubiotics’ GLAAD technology in a range of solid tumors. The total project cost of...
Showing the effect of our Glycopeptides platform in driving directed and robust T-cell immune responses against PD-1 resistant solid tumors...
LAUSANNE, Switzerland, May 27, 2022 — Gnubiotics Sciences, a biotech company pioneering immunomodulatory glycopeptides, today announced that results from its...
Lausanne, Switzerland, May 9, 2022 – Gnubiotics Sciences SA (Gnubiotics) announced today a strategic partnership agreement with ADM, a global...
A trial has found that Animal Milk Oligosaccharides (A.M.O.s) manufactured by leading Swissbiotech experts Gnubiotics Sciences can help prevent the...